$84.00
+3.39 (+4.21%)
Performance
1D
—
1W
—
1M
—
3M
—
6M
—
1Y
+60.03%
YTD
-16.46%
Open$81.37
Previous Close$80.61
Day High$84.33
Day Low$80.26
52W High$151.02
52W Low$44.42
Volume—
Avg Volume879.2K
Market Cap4.05B
P/E Ratio—
EPS$-4.30
SectorBiotechnology
Technical Indicators
Full analysis →
SMA 50
$105.59
Below
SMA 200
$59.11
Above
RSI (14)
39.6
Neutral
Trend
Golden Cross
Bullish
Analyst Ratings
Strong Buy
18 analysts
Price Target
-69.6% upside
Current
$84.00
$84.00
Target
$25.56
$25.56
$16.07
$25.56 avg
$38.64
Key Financials
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Revenue | 856.50M | 842.65M | 828.36M |
| Net Income | -244,490,059 | -213,463,076 | -182,555,570 |
| Profit Margin | -28.6% | -25.3% | -22.0% |
| EBITDA | -292,781,484 | -259,398,727 | -297,826,578 |
| Free Cash Flow | -124,649,561 | -156,876,378 | -179,431,543 |
| Rev Growth | +6.2% | -3.6% | +12.6% |
| Debt/Equity | 1.11 | 1.11 | 1.34 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $264.48 | +0.20% | 74.0 | 466.74B |
| AMGN | Amgen Inc | $393.16 | +1.95% | 23.7 | 207.25B |
| GILD | Gilead Sciences Inc | $150.56 | +0.30% | — | 187.10B |
| VRTX | Vertex Pharmaceuticals Inc | $510.72 | +0.47% | 29.7 | 130.64B |
| REGN | Regeneron Pharmaceuticals | $798.17 | +1.70% | 18.6 | 80.58B |
| ALNY | Alnylam Pharmaceuticals Inc | $244.32 | +1.99% | 40.0 | 32.33B |